Guttenplan, Kevin A. http://orcid.org/0000-0003-4242-4349
Weigel, Maya K.
Adler, Drew I.
Couthouis, Julien http://orcid.org/0000-0002-2378-4595
Liddelow, Shane A. http://orcid.org/0000-0002-0840-1437
Gitler, Aaron D. http://orcid.org/0000-0001-8603-1526
Barres, Ben A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R35NS097263)
Article History
Received: 1 June 2020
Accepted: 6 July 2020
First Online: 27 July 2020
Competing interests
: A.D.G. has served as a consultant for Aquinnah Pharmaceuticals, Prevail Therapeutics, and Third Rock Ventures, and is a scientific founder of Maze Therapeutics. S.A.L. is an academic founder of AstronauTx Ltd. B.A.B. is a co-founder of Annexon Biosciences Inc., a company working to make new drugs for treatment of neurological diseases. The remaining authors declare no competing interests.